Is addition of a third or fourth antiglaucoma medication effective?

Area of Science:

• Ophthalmology
• Glaucoma Research
• Pharmacological Interventions

Background:

• Glaucoma management often requires multiple medications to control intraocular pressure (IOP).
• The efficacy and safety of escalating medical therapy beyond two or three antiglaucoma medications are not well-established.
• Assessing the long-term impact of adding a third or fourth medication is crucial for treatment strategies.

Purpose of the Study:

• To evaluate the intraocular pressure (IOP)-lowering effect of adding a third or fourth antiglaucoma medication.
• To assess the efficacy and safety outcomes over a one-year follow-up period.
• To determine the sustained IOP reduction achieved by intensified medical therapy.

Main Methods:

• Retrospective, nonrandomized, interventional study at a single glaucoma specialist clinic.
• Inclusion of patients receiving a third or fourth antiglaucoma medication added to their existing regimen.
• Measurement of IOP at 2, 6, 9, and 12 months; efficacy defined as >=20% IOP decrease; safety assessed by surgical need or side effects.

Main Results:

• At single time points, 40-60% of patients achieved IOP reduction with a third or fourth medication.
• Kaplan-Meier analysis showed cumulative efficacy success rates of 33% (third med) and 43% (fourth med) at 6 months.
• Cumulative success rates, including safety, decreased to 27% (third med) and 31% (fourth med) at 6 months, and 14% for both at 1 year.

Conclusions:

• Adding a third or fourth antiglaucoma medication can achieve a clinically significant IOP reduction in a substantial proportion of patients at specific time points.
• However, the cumulative probability of sustained efficacy and safety success is limited at 6 months and 1 year.
• Intensifying medical therapy with additional antiglaucoma medications beyond two or three may not consistently achieve significant IOP reduction.